Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
human BCMA-targeted CAR-NK cells
- Development stage
- Unknown
- Lead developer
- Shanghai HRAIN Biotechnology
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
This investigational cell therapy consists of human natural killer (NK) cells genetically engineered to express a chimeric antigen receptor (CAR) targeting B-cell maturation antigen (BCMA). Developed by Hrain Biotechnology Co., Ltd., the therapy is designed to treat relapsed or refractory multiple myeloma and plasma cell leukemia. BCMA is a protein highly expressed on the surface of malignant plasma cells, making it a primary target for immunotherapy in these indications. Unlike traditional CAR-T cell therapies, CAR-NK cells are intended to be used as an 'off-the-shelf' allogeneic product, potentially offering advantages such as a lower risk of cytokine release syndrome (CRS) and graft-versus-host disease (GvHD). The product is currently being evaluated in an early Phase 1 clinical trial to assess its safety, tolerability, and preliminary efficacy.
- Other names
- human BCMA targeted CAR-NK cells injectionanti-BCMA CAR-NK cellsBCMA-targeted CAR-NK cells
02
Targets
BCMA (B-cell maturation antigen)
Beyond the preview
Go deeper on human BCMA-targeted CAR-NK cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on human BCMA-targeted CAR-NK cells.